13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

Amarin reported additional data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) showing that the drug led to a 30% reduction in total CV events vs....
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
21:46 , Jan 17, 2019 |  BC Innovations  |  Finance

Public funding highlights

Public funding highlights Selected developments and initiatives in 4Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
04:32 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million on Nov. 26 in a follow-on as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase...
18:57 , Nov 27, 2018 |  BC Extra  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million in a follow-on late Monday as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase III...
01:45 , Nov 17, 2018 |  BioCentury  |  Product Development

MyoKardia’s myosin mechanism deconvolution

With preclinical proof of concept that its lead candidate mavacamten acts via two distinct mechanisms to treat cardiomyopathy, MyoKardia Inc. is ready to accelerate a pipeline of preclinical programs that exploit the mechanisms separately for...
17:57 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

BioCardia's CardiAMP non-significantly improves 6MWD in roll-in cohort of Phase III for heart failure

BioCardia Inc. (OTCQX:BCDA) reported data from the 10-patient roll-in cohort of the Phase III CardiAMP Heart Failure trial to treat heart failure following a heart attack showing that CardiAMP non-significantly improved mean 6-minute walk distance...
17:28 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Eidos' AG10 leads to >90% TTR stabilization at day 28 in Phase II

Eidos Therapeutics Inc. (NASDAQ:EIDX) said AG10 led to >90% stabilization of transthyretin (TTR) at day 28 in all treated patients in a Phase II trial to treat symptomatic TTR amyloid cardiomyopathy. Twice-daily AG10 significantly increased...
16:04 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Amarin details primary endpoint data for Vascepa, addresses placebo concern

Amarin Corp. plc. (NASDAQ:AMRN) presented detailed primary endpoint data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) and addressed concerns that the mineral oil used in...